The Danish company Reapplix has developed the product LeucoPatch ™ for treatment of severe chronic foot ulcers. The product has in a clinical study conducted at Bispebjerg Hospital Centre for Wound Healing revealed promising results on up to 10 year old wounds. This has resulted in an investment of 7.6 million DKK from SEED Capital.
Patients with diabetes often experience extensive and poorly healing foot ulcers as a consequence of their disease. European studies show that even after a year of treatment, 12% remain in treatment, and more than a fifth has resulted in an amputation. An amputation means longer hospitalization and a strongly reduced quality of life. Reapplix in collaboration with Centre for Wound Healing at Bispebjerg Hospital, conducted a clinical study of the treatment of highly chronic wounds with LeucoPatch ™.Thirteen out of sixteen patients with chronic ulcers (including 5 diabetics) experienced a complete healing or a clinically significant effect by using LeucoPatch ™ in the initial study. All cases were severe chronic wounds, which the patients had for up to 10 years.